Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1911 1
1914 1
1930 1
1933 1
1937 1
1941 1
1946 2
1951 1
1952 1
1957 2
1958 1
1960 4
1961 3
1962 8
1963 2
1964 8
1965 3
1966 9
1967 11
1968 11
1969 14
1970 16
1971 30
1972 33
1973 29
1974 39
1975 147
1976 161
1977 148
1978 150
1979 175
1980 202
1981 226
1982 217
1983 256
1984 243
1985 313
1986 306
1987 335
1988 373
1989 421
1990 471
1991 483
1992 561
1993 548
1994 532
1995 549
1996 578
1997 570
1998 573
1999 566
2000 563
2001 595
2002 612
2003 654
2004 649
2005 728
2006 668
2007 711
2008 740
2009 759
2010 800
2011 853
2012 854
2013 946
2014 949
2015 916
2016 925
2017 945
2018 981
2019 996
2020 1362
2021 1560
2022 1369
2023 1160
2024 1124
2025 1232
2026 757
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,367 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Antibody test negative"
Page 1
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.
METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development o …
METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monocl …
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, Ren Y, Wang S, Fu P, Yang H, Liu Y, Sun J, Nie J, Lei R, Yao Y, Zhang A, Wang S, Ma X, Ouyang Z, Yang H, Wu SY, Cao SW, Wang K, Jiang A, Ouyang Q, Pang D, Wei L, Zha X, Shen Y, Qu X, Wu F, Zhu X, Wang Z, Fan L, Shao ZM. Chen L, et al. JAMA. 2025 Feb 25;333(8):673-681. doi: 10.1001/jama.2024.23560. JAMA. 2025. PMID: 39671272 Free PMC article. Clinical Trial.
IMPORTANCE: Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD- …
IMPORTANCE: Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherap …
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Simpson EL, et al. JAMA Dermatol. 2020 Jan 1;156(1):44-56. doi: 10.1001/jamadermatol.2019.3336. JAMA Dermatol. 2020. PMID: 31693077 Free PMC article. Clinical Trial.
IMPORTANCE: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequ …
IMPORTANCE: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treat …
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.
Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Lee HH, et al. Cancer Cell. 2019 Aug 12;36(2):168-178.e4. doi: 10.1016/j.ccell.2019.06.008. Epub 2019 Jul 18. Cancer Cell. 2019. PMID: 31327656 Free PMC article.
Notably, deglycosylation significantly improves anti-PD-L1 antibody binding affinity and signal intensity, resulting in more accurate PD-L1 quantification and prediction of clinical outcome. This proposed method of PD-L1 antigen retrieval may provide a practical and timely …
Notably, deglycosylation significantly improves anti-PD-L1 antibody binding affinity and signal intensity, resulting in more accurate …
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, Hochreiter R, Bitzer A, Kosulin K, Larcher-Senn J, Mader R, Dubischar K, Zoihsl O, Jaramillo JC, Eder-Lingelbach S, Buerger V, Wressnigg N. Schneider M, et al. Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12. Lancet. 2023. PMID: 37321235 Free PMC article. Clinical Trial.
The primary endpoint was the proportion of baseline negative participants with a seroprotective chikungunya virus antibody level defined as 50% plaque reduction in a micro plaque reduction neutralisation test (muPRNT) with a muPRNT(50) titre of at least 150, …
The primary endpoint was the proportion of baseline negative participants with a seroprotective chikungunya virus antibody lev …
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.
Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Kuang FL, et al. N Engl J Med. 2019 Apr 4;380(14):1336-1346. doi: 10.1056/NEJMoa1812185. N Engl J Med. 2019. PMID: 30943337 Free PMC article. Clinical Trial.
BACKGROUND: Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a monoclonal antibody against interleukin-5 receptor alpha, which is expressed on human eosinophi …
BACKGROUND: Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clini …
A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG, Rodriguez-Rubio M, Mariblanca AR, de Soto LM, García LD, Villatoro JM, Parada JQ, Meseguer ES, Rosales MJ, González J, Arribas JR, Carcas AJ, de la Oliva P, Borobia AM. García IG, et al. Trials. 2020 Jun 3;21(1):466. doi: 10.1186/s13063-020-04436-6. Trials. 2020. PMID: 32493475 Free PMC article.
PARTICIPANTS: Inclusion Criteria: Male or female participants 18 and 80 years of age.Healthcare workers from the public and private Spanish hospital network at risk of SARS-CoV 2 infection.Not having a previous COVID19 diagnosis.Understanding the purpose of the trial and not …
PARTICIPANTS: Inclusion Criteria: Male or female participants 18 and 80 years of age.Healthcare workers from the public and private Span …
A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants.
Sambe T, Miwa T, Yoneyama K, Ishida T, Yamazaki T, Shima M. Sambe T, et al. J Thromb Haemost. 2025 Oct;23(10):3098-3110. doi: 10.1016/j.jtha.2025.06.013. Epub 2025 Jun 17. J Thromb Haemost. 2025. PMID: 40554054 Free article. Clinical Trial.
BACKGROUND: NXT007 is a bispecific antibody that mimics the cofactor function of activated factor (F)VIII and was engineered by modifying emicizumab. ...The elimination half-life of NXT007 was approximately 10 weeks in antidrug antibody-negative participants. …
BACKGROUND: NXT007 is a bispecific antibody that mimics the cofactor function of activated factor (F)VIII and was engineered by modif …
Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial.
Dumoulin QA, Krijbolder DI, Visser K, Lard LR, van der Helm-van Mil AHM. Dumoulin QA, et al. Lancet Rheumatol. 2024 Dec;6(12):e827-e836. doi: 10.1016/S2665-9913(24)00196-6. Epub 2024 Sep 17. Lancet Rheumatol. 2024. PMID: 39303731 Clinical Trial.
However, whether prevention of anti-citrullinated protein antibody (ACPA)-negative rheumatoid arthritis is possible is still unknown. We aimed to assess the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative …
However, whether prevention of anti-citrullinated protein antibody (ACPA)-negative rheumatoid arthritis is possible is still u …
Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A, Katsunuma T, Matsumura T, Komazaki H; Nemolizumab-JP04 Study Group. Igarashi A, et al. Br J Dermatol. 2023 Dec 20;190(1):20-28. doi: 10.1093/bjd/ljad268. Br J Dermatol. 2023. PMID: 37522351 Free article. Clinical Trial.
Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus …
Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep …
31,367 results
You have reached the last available page of results. Please see the User Guide for more information.